EMPEROR-Preserved: Primary Endpoint and Key Quality of Life Results With Empagliflozin vs Placebo in Patients With LVEF ≥50%

November 13-15, 2021; Virtual
Significant improvement vs placebo in composite primary endpoint even in patients with “true” HFpEF.
Format: Microsoft PowerPoint (.ppt)
File Size: 246 KB
Released: December 2, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From Clinical Care Options (CCO), expert commentary on new data in telehealth for heart failure management from AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 13, 2021 Expired: December 12, 2022

From Clinical Care Options (CCO), Dr. Lee Goldberg discusses clinical studies of novel therapies for heart failure management presented at AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 9, 2021 Expired: December 8, 2022

From Clinical Care Options (CCO), expert commentary on new data in heart failure management from AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 8, 2021 Expired: December 7, 2022

From AHA 2021, new analysis from the CHIEF-HF trial of canagliflozin vs placebo in patients with heart failure, as reported by Clinical Care Options (CCO)

Released: December 3, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings